Predict your next investment

HEALTHCARE | Drug Discovery
molecularbiometrics.com

See what CB Insights has to offer

Founded Year

2005

Stage

Dead | Dead

Total Raised

$24.5M

About Molecular Biometrics

Molecular Biometrics is applying metabolomic technologies to develop accurate, non-invasive methodologies for evaluating normal biologic function in health and disease, and for drug discovery and development. The company's technology is being applied in reproductive health, neurodegenerative disease (Alzheimer's disease and Parkinson's disease), maternal fetal medicine, pulmonary metabolism and edema, and lactate metabolism.

Molecular Biometrics Headquarter Location

One Edgewater Drive Suite 110

Norwood, Massachusetts, 02062,

United States

781-501-5600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Molecular Biometrics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Molecular Biometrics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Molecular Biometrics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Molecular Biometrics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.